Bausch+Lomb Results Presentation Deck
Pipeline and Upcoming Milestones¹
Surgical
Product
en Vista® Trifocal (Intraocular Lens)
Stable Visc TM Cohesive OVD
en Vista® Extended Range Monofocal IOL
Extended depth of focus intraocular lens
eye TELLIGENCE TM clinical decision
support software
Lux Premium IOL
3D Microscope
Teneo TM Excimer Laser
BAUSCH + LOMB
Status
Canadian study completed enrollment in 1Q22;
U.S. study completed enrollment in 2Q22
Clinical study enrollment completed 1Q22
Product validations in progress
Clinical study to begin 2Q23
Software validation and launch planning in
progress
Launched in Europe
Approval expected 2022
1. See slide 1 for further information on forward-looking statements.
Expected to initiate clinical trials in 2022
Upcoming Milestone
Expect Canadian clinical study report 3Q22;
Expect U.S. clinical study report 2Q23
Expect Clinical Study Report 2Q22
Expected launch late 2023
Expect 2024/2025 launch
Launching 2H22 (at AAO)
Continued expansion of platform in 2023
Launch expected in 2022
Expected launch in U.S. in 2023
25View entire presentation